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Congenital abnormalities of the kidney and urinary tract
(CAKUT) are the most frequent cause of chronic kidney
disease in children, accounting for about half of all cases.
Although many forms of CAKUT are likely caused by single-
gene defects, mutations in only a few genes have been
identified. In order to detect new contributing genes we
pooled DNA from 20 individuals to amplify all 313 exons of
30 CAKUT candidate genes by PCR analysis and massively
parallel exon resequencing. Mutation carriers were identified
by Sanger sequencing. We repeated the analysis with 20 new
patients to give a total of 29 with unilateral renal agenesis
and 11 with other CAKUT phenotypes. Five heterozygous
missense mutations were detected in 2 candidate genes
(4 mutations in FRAS1 and 1 in FREM2) not previously
implicated in non-syndromic CAKUT in humans. All of these
mutations were absent from 96 healthy control individuals
and had a PolyPhen score over 1.4, predicting possible
damaging effects of the mutation on protein function.
Recessive truncating mutations in FRAS1 and FREM2 were
known to cause Fraser syndrome in humans and mice;
however, a phenotype in heterozygous carriers has not been
described. Thus, heterozygous missense mutations in FRAS1
and FREM2 cause non-syndromic CAKUT in humans.
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Congenital abnormalities of the kidney and urinary tract
(CAKUT) occur in about 3–6 per 1000 live births and
constitute 20–30% of all anomalies identified in the neonatal
period.1,2 They constitute the most frequent cause of end-
stage renal disease in children, accounting for B50% of all
cases.3 To date, there is no prophylaxis for CAKUT available.
CAKUT cover a wide range of structural and functional
malformations that result from defects in the morphogenesis of
the kidney and/or the urinary tract. CAKUTmay occur in a large
number of conditions of various primary or secondary causes.
The hypothesis that CAKUT may be caused in many instances
by single-gene defects is supported by the fact that monogenic
forms of CAKUT in humans and mouse models of CAKUT
have been published.4–7 Such single-gene mutations may cause a
wide phenotypic spectrum of CAKUT that ranges from
vesicoureteral reflux to renal agenesis, because the induction of
the metanephrogenic mesenchyme by the ureteric bud influ-
ences morphogenesis of all three tissue groups of the excretory
system: the ureterovesical junction, the ureter, and the kidney.8
Evidence from human and mouse models suggests the
existence of monogenic causes of CAKUT (Supplementary
Table S1 online). Although many forms of CAKUT in
humans are very likely caused by single-gene defects, only few
causative genes have been identified so far. In our multiethnic
cohort of 538 patients from 456 different families with non-
syndromic CAKUT, we detected mutations of four known
dominant CAKUT genes, TCF2/HNF1b, PAX2, UMOD, and
EYA1, in only 12 families (1.9%).9 Thus, the cases of most of
the individuals in this cohort remained unsolved regarding
their potential molecular genetic cause of CAKUT.
We therefore developed a novel approach of high-
throughput mutation analysis to be performed in pooled
genomic DNA of 20 individuals and 30 candidate genes
simultaneously using exon PCR and massively parallel exon
resequencing.10 The CAKUT candidate genes were genes that
have been implicated in the severe developmental phenotype
of unilateral renal agenesis in humans or mice.
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RESULTS
We pooled two times 20 DNA samples of individuals
with CAKUT (29 with unilateral renal agenesis and 11 with
other forms of CAKUT). We performed exon PCR in 30
candidate genes (Supplementary Table S2 online). Massively
parallel exon resequencing of 342 different exon PCR
products generated was carried out on an Illumina/Solexa
GAII platform (one pool per lane of a flow cell) delivering
about 5.3 million short reads of 39 bases (5.22 million in pool
no. 1 and 5.37 million in pool no. 2). Following gapped
alignment to the human normal reference sequence, 75% of
all reads mapped back to one of the 342 target sequences that
contained the exons plus 100-bp adjacent intronic sequence.
The sequence concatenation of all 342 amplicons amounts to
a total length of 175.7, 68.2 kb of which were exonic coding
regions. The median coverage depth for the coding regions
was 1228-fold (mean 1402-fold). On average, about 95% of
nucleotides in targeted coding regions had at least 400-fold
coverage depth. This translates into a depth of at least 20-fold
per patient, which is sufficient to cause a heterozygous
change.
Mutation carrier identification by Sanger sequencing
Massively parallel exon resequencing of all PCR products of
40 individuals revealed initially a total of 114 variants from
normal reference sequence within the coding regions and
splice sites of the 30 candidate genes analyzed, 47 of which
were known single-nucleotide polymorphisms (SNPs). Eight
additional variants were present in a cohort of 96 Caucasian
healthy control individuals and are thought to be either as yet
unannotated SNPs or false calls due to software base calling
or alignment artifacts. Of the remaining 59 variants, 11 were
predicted to truncate the protein products and 16 others had
a PolyPhen score higher than 1.4 (predicted to be ‘possibly
damaging’). These 27 variants were assumed to affect the
function of encoded proteins, and thus were followed by
direct Sanger sequencing to identify the mutation carrier(s)
out of the respective two pools of 20 individuals each. This
carrier analysis led to the confirmation of 10 of the 27
variants (‘true positives’) in 11 individuals from 11 different
families, whereas 17 of the 27 variants could not be
confirmed (‘false positives’). Segregation study was con-
ducted in all confirmed cases where DNA of relatives was
available and 3 out of 10 variants were not segregating.
The remaining seven variants (Table 1, Figure 1) were
heterozygous missense mutations in four genes. Four
mutations were in FRAS1 (p.L259R, p.D998Y, p.R3273H,
and p.H3757Q) and one in FREM2 (p.T2338I). Mutations in
FRAS1 and FREM2 have never been reported in non-
syndromic CAKUT in humans. All five mutations were
absent from 96 healthy control individuals of Caucasian
origin and 270 control individuals from the ‘1000 Genomes
project’. Two mutations in FRAS1 (p.D998Y and p.H3757Q)
and one mutation in FREM2 (p.T2338I), which were detected
in individuals of Arabic and Indian origin, respectively, were
additionally screened and were absent in 141 ethnically
matched healthy controls. As FRAS1 and FREM2 were known
to inherit recessively, we amplified and sequenced all other
coding exons in respective mutation carriers to exclude the
presence of the second mutation. No further mutations were
found except in A2381 II-2 (FRAS1; R3273H), where an
additional nonsense mutation was detected (R2621X). The
R2621X change was 2349-fold covered with frequency of
4.5% but had been systematically masked out. The two
mutations (R3273H and R2621X) were in trans as R3273H
was heterozygously present only in the mother, whereas
R2621X was heterozygously present only in the father. The
elder female sibling of A2381 II-2 had died in utero of
bilateral renal agenesis and absent bladder; however, the DNA
was not available for study.
Two other variants were novel mutations in known
CAKUT genes: RET (p.V704F) and BMP4 (p.H121R; Table 1,
Figure 1). Family A1143 and A1184 (both Macedonian)
shared the same novel change in BMP4 (p.H121R). Both
mutations were absent from 96 healthy control individuals
and 270 control individuals from the ‘1000 Genomes project’.
Table 1 | Genotypes and phenotypes of eight individuals with unilateral renal agenesis (eight families) with eight different












A2435 II-1 URA Sporadic Macedonia FRAS1 c.776T4G (h) p.L259R 1.692 16/648 (2.5) NA
A1808 II-1 URA Sporadic Kuwait FRAS1 c.2992G4T (h) p.D998Y 2.336 32/1,388 (2.3) NA
A2381 II-2 URA Familiald Austria FRAS1 c.9815G4A (h) p.R3273H 1.695 32/1,085 (2.9) Maternal
FRAS1 c.7861C4T (h) p.R2621X NA 105/2349 (4.5) Paternal
A1425 II-1 URA Sporadic Lebanon FRAS1 c.11268C4A (h) p.H3757Q 2.011 16/1,320 (1.2) NA
A1023 II-1 URA Sporadic India FREM2 c.7013C4T (h) p.T2338I 2.050 29/1,067 (2.7) NA
A1077 II-1 URA Sporadic Kuwait RET c.2110G4T (h) p.V704F 1.537 8/494 (1.6) NA
A1143 II-1 URA Sporadic Macedonia BMP4 c.362A4G (h) p.H121R 2.001 26/826 (3.1) NA
A1184 II-1 URA Sporadic Macedonia BMP4 c.362A4G (h) p.H121R 2.001 800/826 (3.1) Paternal
Abbreviations: h, heterozygous; HRC-1, Human Random Control DNA Panel-1; NA, not available; PICS, predicted impact of coding single-nucleotide polymorphisms; URA,
unilateral renal agenesis.
aAccession numbers: FRAS1, NM_025074; FREM2, NM_207361; RET, NM_020975; BMP4, NM_001202.
bMutation numbering is based on the cDNA position in reference sequences. All changes were absent from 96 healthy control (HRC-1) DNA pool, 270 individuals of the ‘1000
Genomes project’ (http://www.1000genomes.org/page.php), and from additional ethnically matched healthy controls.
cPICS score above 1.4 is considered ‘probably damaging’ (http://genetics.bwh.harvard.edu/pph/).
dA2381 II-1 (older female sibling, died in utero) had bilateral renal agenesis with absent urinary bladder. DNA is not available for study.
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DISCUSSION
We here identified seven different mutations of four different
genes in 7 out of 40 patients with CAKUT, using massively
parallel exon resequencing. Two heterozygous mutations
were novel mutations in known human CAKUT-causing
genes: BMP4 and RET. Five heterozygous mutations were in
two candidate genes that have never been reported in non-
syndromic CAKUT: FRAS1 and FREM2. McGregor et al.11
and Vrontou et al.12 identified recessive mutations in FRAS1
using linkage analysis in families that were affected with
Fraser syndrome, a rare multi-organ disorder characterized
by cryptophthalmos, cutaneous syndactyly, and renal agen-
esis. Fras1 encodes Fras1, a protein containing repeats of the
chondroitin sulfate proteoglycan core domain, the function
of which is to maintain epithelial cell integrity. Fras1 protein
was detected in several developing tissues such as limb, lung,
gut, and kidney. In metanephros, Fras1 was detected in the
extracellular matrix underlying the basal surface of out-
growing ureter and the basement membrane of collecting
tubule.11,12 McGregor et al.11 detected the homozygous Fras1
mutation that leads to premature stop codon (S2200X) in
blebbed (bl) mice, the long-known mouse strain with
phenotype resembling human Fraser syndrome, but in
addition also in utero skin blisters. Both bl/bl mice and
Fras1/ mice developed limb defects and renal agenesis or
dysplasia.11,13 Pitera et al.13 demonstrated that the ureteric
bud of bl/bl mice either failed to sprout or to enter the
metanephric mesenchyme.
All FRAS1 mutations that have been reported in Fraser
syndrome individuals were either homozygous or compound
heterozygous, indicating a recessive genetic mechanism. Most
mutations were truncating.11,14–16 In contrast, we here
observe single heterozygous missense mutations of FRAS1
in non-syndromic unilateral renal agenesis. Although the
disease phenotypes of recessive diseases are generally known
to be absent in heterozygous carriers, there is evidence of
phenotypic expression in heterozygotes of some diseases.
Heterozygous mutations of SALL1 in human cause
Townes–Brocks syndrome, which comprises facial and limb
defects, renal and urinary tract abnormalities, and anorectal
malformations.17 In mice, whereas heterozygous Sall1
mutants mimic severe human phenotypes, Sall1-null mice
only manifest renal agenesis without other organ involve-
ment.18,19 Kiefer et al.18 demonstrated that the truncated
Sall1 protein could interact with all Sall proteins and have
deleterious effects on all Sall functions in the cell. The other
example is Eya1 where both heterozygous and homozygous
mutant mice have renal abnormalities and hearing defects
similar to human branchio-oto-renal syndrome.20
In an individual with compound heterozygous mutations
(R3273H and R2621X), as this individual had only unilateral
renal agenesis, but not full-spectrum Fraser syndrome, it was
FRAS1, A2435, 776T>G, L259R
FRAS1, A1425, 11268C>A, H3757Q FREM2, A1023, 7013C>T, T2338I EMX2, A3297, 340C>G, R114G BMP4, A1143, 362A>G, H121R
BMP4, A1184, 362A>G, H121R RET, A1077, 2110G>T, V704F HOXA11, A1890, 848G>A, R283H SPRY1, A1261, 823C>T, P275S
FRAS1, A1808, 2992G>T, D998Y FRAS1, A2381, 9815G>A, R3273H FRAS1, A2381, 7861C>T, R2621X
Figure 1 | Sequence chromatograms of 11 confirmed variants identified in 11 individuals with unilateral renal agenesis. Gene name,
patient identifier, nucleotide change, and inferred amino-acid alteration are given above sequence traces. The mutation position is
indicated with an arrow. Wild-type sequence chromatograms are shown below mutated sequences. Reading frames are underlined.
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possible that only the truncating allele caused the phenotype.
On the other hand, based on the presence of more
severe CAKUT phenotypes in the deceased sibling (died
in utero, no data on other phenotypes), and on the fact that
the mutations were in trans, this might be compound
heterozygous inheritance. Variability in expression is
uncommon in recessive diseases, but was reported in
autosomal recessive polycystic kidney disease/congenital
hepatic fibrosis, hereditary hemochromatosis, and familial
hypobetalipoproteinemia.
Frem2, a FRAS1-related extracellular matrix protein 2
gene, was identified as segregating in the mouse myUcl strain
that showed phenotypes similar to that of Fras1/ mutant
mice. Frem2 was expressed in mesonephric and metanephric
epithelium, especially in the ureteric bud.21 Frem2 shares
several structural domains with Fras1, including the core
region of 12 chondroitin sulfate proteoglycans. Jadeja et al.21
detected a homozygous mutation in FREM2 in two families
with Fraser syndrome not linked to FRAS1. To date, there
have been only two different homozygous mutations of
FREM2 reported, representing three unrelated families with
Fraser syndrome.21,22 Homozygous FREM2 mutations oc-
curred in syndromic form of Fraser syndrome, whereas we
found heterozygous FREM2 mutations in individuals with
non-syndromic unilateral renal agenesis.
Criteria that established causality for rare genetic variants
are usually (i) the absence of the allele from 450 ethnically
matched control individuals, (ii) ‘allelic strength’ as sup-
ported by the finding that the variant leads to truncation or
absence of the gene product (mutation of start codon,
obligatory splice site, stop-codon mutations, frameshift
mutations), (iii) previous publication of the allele as disease
causing, and (iv) functional studies in cell-based systems or
animal models, if available. In our study, many of these
criteria apply because (i) we confirmed the absence of all
mutations in 96 healthy control individuals of European
origin, 270 control individuals from the ‘1000 Genomes
project’, and additional 141 ethnically matched healthy
controls; (ii) although most mutations are not truncating,
they are well conserved and are predicted to be ‘damaging’
using the prediction software; and (iii) mutations in these
genes were known to cause CAKUT as part of Fraser
syndrome.
To evaluate the frequency of FRAS1 and FREM2 variants in
normal population, we searched in ‘1000 Genomes’ data set
and found 81 and 20 exonic SNPs in FRAS1 and FREM2,
respectively, of which B50% (40 in FRAS1 and 9 in FREM2)
are synonymous variants. Among non-synonymous variants,
all 11 changes in FREM2 and 36 out of 41 in FRAS1 were
annotated in dbSNP132 with a frequency above 1%, leaving
only 5 variants in FRAS1 unannotated. In four probands with
FRAS1 mutations, there are three additional FRAS1 exonic
variants with PolyPhen scores between 1.435 and 1.575. These
three variants with ‘possibly damaging’ PolyPhen score were
annotated as known SNPs with allele frequency between 5 and
44.7%, which very likely excludes them as functional alleles.
Here we emphasize the advantages of using DNA pooling
and massively parallel exon resequencing over the conven-
tional method of exon PCR in single individuals, which is
expensive, highly labor intensive, and hardly feasible in
diseases with broad genetic heterogeneity. The estimated cost
of next-generation sequence analysis in our laboratory was
reduced to be about $50–60 per individual for 313 exons.23 In
this study, we were able to identify potential CAKUT-causing
mutations in 8 out of 40 individuals (20%). In a study by
Otto et al.24, the exact same approach using pooled DNA was
applied to 18 patients with known mutations in nephro-
nophthisis-associated ciliopathy genes. After massively par-
allel exon resequencing of 376 different pooled PCR products
derived from the DNA pool of 18 different mutation carriers,
the analysis revealed 22 out of 24 known mutations (92%) or
8% false negative.24 This weakness may partially be overcome
by sequencing more than one lane upon Illumina sequencing
of pooled PCR products. Another weakness may lie in the
fact that confirmation of changes by Sanger sequencing is
cumbersome. This limitation can now be addressed by using
the array-based Integrated Fluidic Circuit by Fluidigm
platform with 48-sample throughput.25 We also might miss
mutations in areas of low coverage (o400-fold), mutations
in promoter or intronic exon splice enhancers, insertions or
deletions larger than 2 bp in length, and complete exon
deletions. To overcome the relatively high false-positive error
rate delivered by massively parallel exon resequencing, we
prioritized our analysis to detect mutations that are predicted
to be damaging. The improvement in coverage might solve
this problem in future projects.
MATERIALS AND METHODS
Human subjects
Blood or DNA samples were obtained from 40 individuals
diagnosed with CAKUT from 38 different families. The diagnosis
was made by pediatric nephrologists on the basis of imaging studies.
After informed consent was obtained, detailed clinical data and
pedigree information was referred to us by the specialists through a
standardized clinical questionnaire (http://www.renalgenes.org).
The cohort of 40 individuals included 29 (72.5%) individuals
diagnosed with unilateral renal agenesis, 3 (7.5%) individuals with
renal hypodysplasia, 7 (17.5%) individuals with vesicoureteral
reflux, and 1 (2.5%) individual with bilateral duplex systems.
Whole-genome amplification and DNA pooling
To normalize various DNA samples, whole-genome amplification
was performed on DNA of 40 different individuals and 96 healthy
control samples using Phi29-based DNA polymerase strand
displacement amplification (GenomiPhi DNA amplification kit,
GE Healthcare, Piscataway, NJ). Subsequently, whole-genome-
amplified DNA was purified using 96-well spin columns (Rapid
96TM PCR purification system, Marligen Biosciences, Reutlingen,
Germany). DNA of 20 individuals were pooled at 2 mg each and
diluted to 60 ng/ml. Pooling was repeated to represent 40 individuals.
In addition, an equimolar DNA pool was generated by pooling 96
DNA samples derived from healthy individuals of Caucasian origin
(Human Random Control DNA Panel-1 (HRC-1); European
Collection of Cell Cultures, Salisbury, UK).
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PCR amplification and massively parallel exon resequencing
All 313 exons (342 amplicons) of 30 candidate genes, ATGR2, BMP4,
CDC5L, EMX2, EYA1, FOXC1, FRAS1, FREM2, GATA1, GDF11,
GDNF, GFRA1, GREM1, HOX11, HOXA11, KAL1, PAX2, RET,
ROBO2, SALL1, SIX1, SIX2, SIX4, SIX5, SLIT2, SPRY1, TCF2
(HNF1b), UPK3A, and USF2, were individually amplified using
exon-flanking primers (Supplementary Table S2 online) on each of
the DNA pools. PCR products from the same pool were combined
and enzymatically modified. The modified PCR fragment mixture
was then used to construct an Illumina sequencing library using
‘Genomic DNA Sample Prep Kit’ as previously described.10 Each
library was run on a single lane of a Solexa/Illumina Genome
Analyzer GAII platform, generating about 15–20 million single-end
sequence reads of 39 bases each.
Sequence analysis and mutation carrier identification
Sequence alignment was performed with CLC Genomics Workbench
software (CLC-bio, Aarhus, Denmark) using imported and
annotated human reference genome assembly NCBI36/hg18 as a
reference. Sequence reads were mapped to exonic coding regions
plus adjacent 100 bp intronic sequence of all 313 exons. Variant calls
were obtained using the following filter parameters: Coverage
X400-fold, variant frequency X1%, and a minimum variant count
of five reads. The variant analysis included coordinates of obligatory
splice sites, and all variants predicted to change the amino-acid
sequence (missense, nonsense, and coding indels). Variants present
in dbSNP130, the ‘1000 Genomes Project’ (270 control individuals,
http://www.1000genomes.org/page.php), or in the healthy control
pool of 96 individuals (HRC-1) were excluded from further analysis.
To prioritize for downstream analysis, we scored missense variants
according to the information of evolutionary conservation and the
likelihood of a potential protein-damaging effect using PolyPhen
software predictions (http://genetics.bwh.harvard.edu/pph/).26 All
variants with a predicted ‘probably damaging’ or ‘possibly dam-
aging’ effect and a score above 1.4 were further analyzed. The
selected variants were amplified by PCR for each individual in the
corresponding DNA pool with subsequent Sanger sequencing to
identify the mutation carrier.
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